2nd Circ. Considers Reinstating Fosamax Witness
By Eric Hornbeck ( October 21, 2010, 7:00 PM EDT) -- A federal appeals court panel has questioned the value of reinstating a doctor's "equivocal" testimony in a bellwether case in product liability multdistrict litigation over Merck & Co. Inc.'s osteoporosis drug Fosamax....
Law360 is on it, so you are, too.
A Law360 subscription puts you at the center of fast-moving legal issues, trends and developments so you can act with speed and confidence. Over 200 articles are published daily across more than 60 topics, industries, practice areas and jurisdictions.
A Law360 subscription includes features such as
- Daily newsletters
- Expert analysis
- Mobile app
- Advanced search
- Judge information
- Real-time alerts
- 450K+ searchable archived articles
And more!
Experience Law360 today with a free 7-day trial.